156 related articles for article (PubMed ID: 8538200)
1. Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs.
Schwartz AG; Pashko LL
J Cell Biochem Suppl; 1995; 22():210-7. PubMed ID: 8538200
[TBL] [Abstract][Full Text] [Related]
2. Cancer chemoprevention with the adrenocortical steroid dehydroepiandrosterone and structural analogs.
Schwartz AG; Pashko LL
J Cell Biochem Suppl; 1993; 17G():73-9. PubMed ID: 8007713
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin papilloma formation in mice by dehydroepiandrosterone and two synthetic analogs.
Schwartz AG; Fairman DK; Polansky M; Lewbart ML; Pashko LL
Carcinogenesis; 1989 Oct; 10(10):1809-13. PubMed ID: 2529051
[TBL] [Abstract][Full Text] [Related]
4. Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats.
Schwartz AG; Lewbart ML; Pashko LL
Cancer Res; 1988 Sep; 48(17):4817-22. PubMed ID: 2970293
[TBL] [Abstract][Full Text] [Related]
5. Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: relationship to antihyperglycemic effects.
Leiter EH; Beamer WG; Coleman DL; Longcope C
Metabolism; 1987 Sep; 36(9):863-9. PubMed ID: 2957567
[TBL] [Abstract][Full Text] [Related]
6. Dehydroepiandrosterone and its derivatives: potentially novel anti-proliferative and chemopreventive agents.
Matsuzaki Y; Honda A
Curr Pharm Des; 2006; 12(26):3411-21. PubMed ID: 17017935
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the enhancing effects of dehydroepiandrosterone with the structural analog 16 alpha-fluoro-5-androsten-17-one on aflatoxin B1 hepatocarcinogenesis in rainbow trout.
Orner GA; Donohoe RM; Hendricks JD; Curtis LR; Williams DE
Fundam Appl Toxicol; 1996 Nov; 34(1):132-40. PubMed ID: 8937900
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumor formation in mice by 16 alpha-fluoro-5-androsten-17-one and its reversal by deoxyribonucleosides.
Pashko LL; Lewbart ML; Schwartz AG
Carcinogenesis; 1991 Nov; 12(11):2189-92. PubMed ID: 1934309
[TBL] [Abstract][Full Text] [Related]
9. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor development by dehydroepiandrosterone and related steroids.
Schwartz AG; Pashko L; Whitcomb JM
Toxicol Pathol; 1986; 14(3):357-62. PubMed ID: 3024302
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention by dehydroepiandrosterone and indomethacin in a rat multiorgan carcinogenesis model.
Shibata M; Hasegawa R; Imaida K; Hagiwara A; Ogawa K; Hirose M; Ito N; Shirai T
Cancer Res; 1995 Nov; 55(21):4870-4. PubMed ID: 7585522
[TBL] [Abstract][Full Text] [Related]
12. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity.
Schwartz AG; Pashko LL
Ageing Res Rev; 2004 Apr; 3(2):171-87. PubMed ID: 15177053
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone.
McCormick DL; Johnson WD; Kozub NM; Rao KV; Lubet RA; Steele VE; Bosland MC
Carcinogenesis; 2007 Feb; 28(2):398-403. PubMed ID: 16952912
[TBL] [Abstract][Full Text] [Related]
14. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone.
Gordon GB; Shantz LM; Talalay P
Adv Enzyme Regul; 1987; 26():355-82. PubMed ID: 2960133
[TBL] [Abstract][Full Text] [Related]
15. DHEA, important source of sex steroids in men and even more in women.
Labrie F
Prog Brain Res; 2010; 182():97-148. PubMed ID: 20541662
[TBL] [Abstract][Full Text] [Related]
16. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology.
Labrie F; Bélanger A; Cusan L; Candas B
J Clin Endocrinol Metab; 1997 Aug; 82(8):2403-9. PubMed ID: 9253308
[TBL] [Abstract][Full Text] [Related]
17. Dehydroepiandrosterone and two structural analogs inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of prostaglandin E2 content in mouse skin.
Hastings LA; Pashko LL; Lewbart ML; Schwartz AG
Carcinogenesis; 1988 Jun; 9(6):1099-102. PubMed ID: 2967126
[TBL] [Abstract][Full Text] [Related]
18. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of adjuvant-induced arthritis by 16 alpha-fluoro-5-androsten-17-one.
Schwartz AG; Pashko LL
Mil Med; 2002 Feb; 167(2 Suppl):60-3. PubMed ID: 11873519
[TBL] [Abstract][Full Text] [Related]
20. Dehydroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication.
Henderson E; Yang JY; Schwartz A
AIDS Res Hum Retroviruses; 1992 May; 8(5):625-31. PubMed ID: 1381206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
